Provectus reports Phase Ib data for PV-10 in melanoma

In October, Provectus Biopharmaceuticals Inc. (OTCQB:PVCT) reported preliminary data from 10 evaluable patients with stage IV metastatic melanoma in the Phase Ib portion of a Phase Ib/II trial

Read the full 280 word article

User Sign In